![logo](/logos/KNTE.webp)
Kinnate Biopharma Inc.
NASDAQ:KNTE
2.65 (USD) • At close April 3, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Kinnate Biopharma Inc. |
Symbool | KNTE |
Munteenheid | USD |
Prijs | 2.65 |
Beurswaarde | 124,990,960 |
Dividendpercentage | 0% |
52-weken bereik | 1.04 - 7.185 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Nima Farzan M.B.A. |
Website | https://www.kinnate.com |
An error occurred while fetching data.
Over Kinnate Biopharma Inc.
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)